Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-02-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司第八届监事会第二十次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a supervisory board meeting regarding a proposed issuance of A shares to specific investors. It includes specifics on the issuance terms, pricing, lock-up periods, use of proceeds, and related approvals. The content is focused on capital raising activities and the approval process for a share issuance. It is not a full financial report, earnings release, or management discussion. It is not a simple announcement of a report publication but a substantive disclosure about financing plans and approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2023-02-27 Chinese
金陵药业股份有限公司关于最近五年被证券监管部门和证券交易所采取监管措施或处罚的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding regulatory measures or penalties taken by securities regulatory authorities or stock exchanges over the past five years. It details the company's compliance and corrective actions related to a regulatory letter received in 2019. The document is short (1005 characters) and serves as a disclosure or regulatory update rather than a financial report or detailed audit. It does not contain financial statements or detailed financial data. It is a regulatory announcement about compliance and regulatory history, fitting best under Regulatory Filings (RNS).
2023-02-27 Chinese
金陵药业股份有限公司关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2023 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed and voted on, and instructions for shareholders. It is not a report of financial results or an audit, nor is it a transcript or presentation. It is a formal announcement to shareholders about the meeting and the agenda items, including proposals related to share issuance and other corporate matters. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is over 5,000 characters and contains detailed information about the meeting and voting, not just a brief announcement or a report publication notice. Therefore, the correct classification is PSI.
2023-02-27 Chinese
金陵药业股份有限公司未来三年（2023年—2025年度）股东回报规划
Notice of Dividend Amount Classification · 90% confidence The document is a detailed plan outlining the company's shareholder return policy for the next three years (2023-2025). It discusses dividend distribution methods, conditions for cash dividends, decision-making procedures, and mechanisms for adjusting the plan. It is not a financial report, earnings release, or regulatory filing but a formal policy document related to dividends and shareholder returns. This fits best under the category of Notice of Dividend Amount (DIV), as it pertains to dividend policy and shareholder return planning rather than an actual dividend payment announcement or financial report. The document length is 3098 characters, which is substantial and contains detailed policy information, not just an announcement or brief notice.
2023-02-27 Chinese
金陵药业股份有限公司关于2023年度向特定对象发行A股股票摊薄即期回报、采取填补措施的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the dilution of immediate returns due to a specific issuance of A shares to particular investors in 2023. It includes detailed analysis of the impact on financial indicators, risk warnings, necessity and rationality of the issuance, investment projects, and commitments by the company’s board and controlling shareholders to measures mitigating dilution effects. The document references regulatory requirements and commitments but does not contain actual financial statements or comprehensive financial data. It is primarily an announcement about a capital raising event and related shareholder impact and commitments, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6797 characters) and content support this classification with high confidence.
2023-02-27 Chinese
金陵药业股份有限公司2023年度向特定对象发行A股股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度向特定对象发行A股股票募集资金使用的可行性分析报告" which translates to "2023 Feasibility Analysis Report on the Use of Funds Raised by Private Placement of A Shares." It details the planned use of funds raised from a specific share issuance, including investment projects, expected returns, and impact on the company. The content focuses on capital raising and the allocation of proceeds, including project descriptions and financial implications. This is not a full annual or interim financial report, nor an earnings release or management discussion. It is a detailed report related to capital raising and financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support it being a full report rather than a brief announcement or regulatory filing.
2023-02-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.